Synergistic Antitumor Effect of BKM120 with Prima-1Met Via Inhibiting PI3K/AKT/mTOR and CPSF4/hTERT Signaling and Reactivating Mutant P53

Background/Aims: PI3KCA and mutant p53 are associated with tumorigenesis and the development of cancers. NVP-BKM120, a selective pan-PI3K inhibitor, exerts the antitumor activity by suppressing the PI3K signaling pathway. Prima-1Met, a low molecular weight compound, can rescue the gain-of-function of mutant p53 by restoring its transcriptional function. In this study, we investigated whether PI3K inhibition combined with mutant p53 reactivation could enhance the antitumor effect in thyroid cancer cells. Methods: The effects of BKM120 and Prima-1Met on the proliferation, apoptosis, migration and invasion of thyroid cancer cells were measured by MTT, colony formation, flow cytometry, wound-healing and transwell assays, respectively. Thyroid differentiation was assessed by detecting the expression levels of specific markers using RT-PCR and Western blot. The in vivo antitumor efficacy was analyzed in a mouse xenograft model. Results: The combinational treatment of BKM120 and Prima-1Met significantly enhanced the inhibitions of cell viability, colony formation, migration and invasion, and the induction of apoptosis in thyroid cell lines, and synergistically suppressed tumor xenograft growth by inhibiting the PI3K/Akt/mTOR and EMT signaling pathways, up-regulating p53 targeted genes, and triggering the release of cytochrome c. Moreover, the combination of BKM120 and Prima-1Met suppressed the stemlike traits of thyroid cancer cells and promoted their differentiation by upregulating the expression of thyroid-specific differentiation markers and repressing the expression of cancer stem cell markers. Furthermore, the mechanism study demonstrated that the combinational treatment synergistically abrogated the binding of CPSF4 at the promoter of hTERT and thus suppressed hTERT expression. Consistently, overexpression of hTERT rescued the inhibitions of cell viability, invasion and stem-like traits mediated by the combination of BKM120 and Prima-1Met. Conclusion: Our results showed that the combination of BKM120 with Prima-1Met synergistically suppressed the growth of thyroid cancer cells and tumor xenografts via inhibiting PI3K/Akt/mTOR and CPSF4/hTERT signaling and reactivating mutant p53.

[1]  M. Cabanillas.  Faculty of 1000 evaluation for Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. , 2018 .

[2]  C. La Motta,et al.  Novel therapeutic clues in thyroid carcinomas: The role of targeting cancer stem cells , 2017, Medicinal research reviews.

[3]  K. Burman,et al.  Targeted therapies in thyroid cancer: an extensive review of the literature , 2016, Expert review of clinical pharmacology.

[4]  Bin Xu,et al.  Genomic Landscape of poorly Differentiated and Anaplastic Thyroid Carcinoma , 2016, Endocrine Pathology.

[5]  P. Santisteban,et al.  ß-catenin signaling is required for RAS-driven thyroid cancer through PI3K activation , 2016, Oncotarget.

[6]  V. Rotter,et al.  Targeting mutant p53 for cancer therapy , 2016, Aging.

[7]  Gregory W. Peek,et al.  Down-regulation of hTERT and Cyclin D1 transcription via PI3K/Akt and TGF-β pathways in MCF-7 Cancer cells with PX-866 and Raloxifene. , 2016, Experimental cell research.

[8]  S. Beriwal,et al.  Anaplastic thyroid cancer: Prognostic factors, patterns of care, and overall survival , 2016, Head & neck.

[9]  Quentin Liu,et al.  hnRNPA2/B1 activates cyclooxygenase‐2 and promotes tumor growth in human lung cancers , 2016, Molecular oncology.

[10]  C. Sander,et al.  Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. , 2016, The Journal of clinical investigation.

[11]  Shan Jin,et al.  Signaling Pathways in Thyroid Cancer and Their Therapeutic Implications , 2016, Journal of clinical medicine research.

[12]  A. Alzahrani,et al.  TERT Promoter Mutations in Thyroid Cancer , 2016, Hormones and Cancer.

[13]  M. Soleimani,et al.  Cancer stem-like cell behavior in anaplastic thyroid cancer: A challenging dilemma. , 2016, Life sciences.

[14]  Wenlin Huang,et al.  CREB‐binding protein regulates lung cancer growth by targeting MAPK and CPSF4 signaling pathway , 2016, Molecular oncology.

[15]  E. di Tomaso,et al.  PI3K inhibitors as new cancer therapeutics: implications for clinical trial design , 2016, OncoTargets and therapy.

[16]  E. di Tomaso,et al.  PI3K inhibitors as new cancer therapeutics: implications for clinical trial design , 2016, OncoTargets and therapy.

[17]  L. Trani,et al.  A Phase I Trial of BKM 120 ( Buparlisib ) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor – Positive Metastatic Breast Cancer , 2016 .

[18]  T. Iwakuma,et al.  Targeting Oncogenic Mutant p53 for Cancer Therapy , 2015, Front. Oncol..

[19]  Obi L. Griffith,et al.  A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer , 2015, Clinical Cancer Research.

[20]  M. Shah,et al.  Anaplastic thyroid cancer , 2015, Current opinion in endocrinology, diabetes, and obesity.

[21]  E. Kebebew,et al.  Management of anaplastic thyroid cancer. , 2015, Gland surgery.

[22]  F. Caponigro,et al.  Targeted therapy: a new hope for thyroid carcinomas. , 2015, Critical reviews in oncology/hematology.

[23]  R. Latif,et al.  Human embryonic stem cells form functional thyroid follicles. , 2015, Thyroid : official journal of the American Thyroid Association.

[24]  S. Benvenga,et al.  New Therapies for Dedifferentiated Papillary Thyroid Cancer , 2015, International journal of molecular sciences.

[25]  M. Scaltriti,et al.  Buparlisib, an oral pan-PI3K inhibitor for the treatment of breast cancer , 2015, Expert opinion on investigational drugs.

[26]  K. Wiman,et al.  Mutant p53 reactivation by small molecules makes its way to the clinic , 2014, FEBS letters.

[27]  Wenlin Huang,et al.  CPSF4 activates telomerase reverse transcriptase and predicts poor prognosis in human lung adenocarcinomas , 2014, Molecular oncology.

[28]  R. Celestino,et al.  TERT Promoter Mutations Are a Major Indicator of Poor Outcome in Differentiated Thyroid Carcinomas , 2014, The Journal of clinical endocrinology and metabolism.

[29]  Quentin Liu,et al.  Upregulation of Cleavage and Polyadenylation Specific Factor 4 in Lung Adenocarcinoma and Its Critical Role for Cancer Cell Survival and Proliferation , 2013, PloS one.

[30]  Yong Li,et al.  Acquisition of epithelial–mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance , 2013, Cell Death and Disease.

[31]  J. Bishop,et al.  Highly prevalent TERT promoter mutations in aggressive thyroid cancers. , 2013, Endocrine-related cancer.

[32]  A. Shaha,et al.  Anaplastic thyroid cancer. , 2013, Oral oncology.

[33]  W. Sewell,et al.  Phenotypic Characterization of Metastatic Anaplastic Thyroid Cancer Stem Cells , 2013, PloS one.

[34]  M. Xing,et al.  Molecular pathogenesis and mechanisms of thyroid cancer , 2013, Nature Reviews Cancer.

[35]  David S. Lapointe,et al.  A Synthetic Interaction Screen Identifies Factors Selectively Required for Proliferation and TERT Transcription in p53-Deficient Human Cancer Cells , 2012, PLoS genetics.

[36]  P. Vigneri,et al.  Reactivation of p53 mutants by p53 reactivation and induction of massive apoptosis in thyroid cancer cells , 2012 .

[37]  A. González-Angulo,et al.  Targeting the PI3K signaling pathway in cancer therapy , 2012, Expert opinion on therapeutic targets.

[38]  C. Montagna,et al.  Thyrocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors , 2011, Oncotarget.

[39]  K. Wiman,et al.  PRIMA-1MET/APR-246 targets mutant forms of p53 family members p63 and p73 , 2010, Oncogene.

[40]  T. Hupp,et al.  Drug discovery and mutant p53. , 2010, Trends in cell biology.

[41]  H. Dralle,et al.  Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas , 2010, Oncogene.

[42]  M. Xing,et al.  Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. , 2010, Thyroid : official journal of the American Thyroid Association.

[43]  Matthew D. Ringel,et al.  The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors , 2010, Molecular and Cellular Endocrinology.

[44]  Kwok-Kin Wong,et al.  Targeting the PI3K signaling pathway in cancer. , 2010, Current opinion in genetics & development.

[45]  T. Hupp,et al.  Series : Thirty years of p 53 Drug discovery and mutant p 53 , 2010 .

[46]  J. Prat,et al.  Concomitant PI3K–AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis , 2009, Modern Pathology.

[47]  J. McNamara.  Cancer Stem Cells , 2007, Methods in Molecular Biology.

[48]  J. Roth,et al.  Tumor-specific Activation of Human Telomerase Reverses Transcriptase Promoter Activity by Activating Enhancer-binding Protein-2β in Human Lung Cancer Cells* , 2007, Journal of Biological Chemistry.

[49]  A. Fersht,et al.  Rescuing the function of mutant p53 , 2001, Nature Reviews Cancer.

[50]  C. Eng,et al.  Transient ectopic expression of PTEN in thyroid cancer cell lines induces cell cycle arrest and cell type-dependent cell death. , 2001, Human molecular genetics.

[51]  L. Hsieh,et al.  p53 gene mutation in thyroid carcinoma. , 1996, Cancer letters.

[52]  R. Tiwari,et al.  Who is (are) the author(s) , 1977 .

[53]  P DESAIVE,et al.  [Thyroid cancer]. , 1951, Revue medicale de Liege.